The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CASI | -69.73% | -90.51% | -37.56% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +901% |
CASI Pharmaceuticals, Inc. engages in developing and commercializing therapeutics and pharmaceutical products. The company was founded on January 10, 2023 and is headquartered in Beijing, China.
Investors don't like that the company is hitting up the market for more cash.
Investors are pleased with a plan to sell generic Viread in China.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $4.18M | 4.9% |
| Gross Profit | $2.06M | -0.4% |
| Gross Margin | 49.29% | -2.7% |
| Market Cap | $18.28M | -75.2% |
| Market Cap / Employee | $0.08M | 0.0% |
| Employees | 233 | 0.0% |
| Net Income | -$13.38M | -92.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.74M | -29.3% |
| Accounts Receivable | $5.36M | -20.9% |
| Inventory | 3.4 | -76.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $18.73M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -110.99% | -70.4% |
| Return On Invested Capital | -229.55% | -166.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.48 | 2.40 | 18.08 | -2.27 | -147.62% |
| Price to Sales | 4.43 | 1.54 | 1.07 | 0.58 | -82.60% |
| Price to Tangible Book Value | 8.53 | 2.58 | 20.75 | -2.20 | -141.42% |
| Return on Equity | -122.9% | -136.0% | -301.8% | -1094.5% | 908.75% |
| Total Debt | $19.12M | $22.14M | $18.49M | $18.73M | 1.46% |
CASI earnings call for the period ending September 30, 2020.
CASI earnings call for the period ending June 30, 2020.
CASI earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
